Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Doses of Tesamorelin in Stable Ambulatory COPD Subjects With Muscle Wasting
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2022
Price :
$35
*
At a glance
- Drugs Tesamorelin (Primary)
- Indications Muscular atrophy
- Focus Therapeutic Use
- Sponsors Theratechnologies
- 29 May 2014 New trial record
- 08 Dec 2011
- 08 Sep 2011